Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2006

View Archived Issues

CombinatoRx and CFFT collaborate on synergistic drug combinations for CF

Rib-X and Wakunaga Pharmaceutical sign license agreement for WQ-3034

Phase III safety study of AIR insulin completes enrollment

Novartis launches ENACT program for expanded access to nilotinib

Novartis licenses rights to Albuferon

New phase III study of darusentan in resistant hypertension

Phase II study for PXD-101 in AML

Phase III results of lisdexamfetamine in ADHD presented

Stimulant medications most effective in treating attention deficit hyperactivity disorder

PQ-401: targeting IGF-IR to reduce breast cancer cell growth

AZ-001 studied in phase IIb trial for migraine

Recent patents describe new treatments for endocrine-related disorders

Biovest files to expand phase III study of BiovaxID to Russia and Ukraine

Clinical Data targeting 2006 launch of genetic test for warfarin response

Orphan drug designation for Xechem's 5-HMF in sickle cell disease

Development plans for three dosage forms of methylnaltrexone

Abilify launched in Japan

Agents for gastrointestinal disorders claimed in recent patents

Amorcyte begins phase I cell therapy for cardiovascular disease

FDA response to pre-IND for FV-100 for shingles

Novel treatment for HIV infection reported by Panacos

Japanese launch for Detrusitol for overactive bladder

Merck & Co. brings forward anticipated NDA filing for MK-0431A

Competact for type 2 diabetes recommended for approval in Europe

Betaferon approved in Europe as first-line treatment for earliest stages of MS

Humira approved in Europe for ankylosing spondylitis

Multiple kinase inhibitor shows oral activity in NSCLC

Promising preliminary phase I data for human anti-EGFR MAb

Positive phase II results for SP-1049C in esophageal adenocarcinoma; phase III planned

Multiple-dose study of BMS-582664 in patients with metastatic refractory solid tumors

Favorable clinical and preclinical data presented on pan-Bcl-2 inhibitor GX15-070

First clinical results reported for Plk1 inhibitor BI-2536

Novel ceramide analogue shows preclinical efficacy against head and neck tumors with gemcitabine